TRex Bio (NASDAQ:TRXB) Now Covered by Zacks Research

Stock analysts at Zacks Research assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a report released on Tuesday, Zacks reports. The brokerage set a “hold” rating on the stock.

Several other research firms have also recently commented on TRXB. Wedbush started coverage on shares of TRex Bio in a research note on Monday. They set an “outperform” rating and a $30.00 target price for the company. Evercore initiated coverage on shares of TRex Bio in a report on Tuesday. They issued a “strong-buy” rating for the company. Stifel Nicolaus began coverage on shares of TRex Bio in a research report on Tuesday. They issued a “buy” rating and a $39.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of TRex Bio in a report on Tuesday. They set an “overweight” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of TRex Bio in a research report on Tuesday. They set an “overweight” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $29.67.

TRex Bio Stock Performance

TRXB opened at $13.55 on Tuesday. TRex Bio has a 1-year low of $12.50 and a 1-year high of $16.56.

Insider Activity

In other news, major shareholder Alexandria Venture Investments bought 178,571 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the purchase, the insider owned 1,346,501 shares of the company’s stock, valued at $18,851,014. This trade represents a 15.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.